Tilray Brands (NASDAQ:TLRY) Rating Increased to Strong-Buy at TD Securities

Tilray Brands (NASDAQ:TLRY) was upgraded by stock analysts at TD Securities to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday. ATB Cormark Capital Markets lowered their price target on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 2nd. Weiss Ratings downgraded Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Roth Capital raised Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research note on Thursday, April 2nd. Finally, TD Cowen lowered their target price on Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Tilray Brands Stock Up 8.1%

Tilray Brands stock opened at $4.54 on Friday. Tilray Brands has a fifty-two week low of $3.67 and a fifty-two week high of $23.20. The firm has a market capitalization of $529.14 million, a price-to-earnings ratio of -4.20 and a beta of 1.89. The stock’s fifty day moving average is $4.67 and its two-hundred day moving average is $6.26. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.66 and a current ratio of 2.21.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%.The firm had revenue of $281.71 million for the quarter, compared to analyst estimates of $246.30 million. Analysts predict that Tilray Brands will post -0.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Tilray Brands

Several hedge funds have recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in Tilray Brands during the fourth quarter worth approximately $38,000. Pictet Asset Management Holding SA grew its stake in shares of Tilray Brands by 38.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company’s stock valued at $119,000 after buying an additional 5,145 shares during the period. Schonfeld Strategic Advisors LLC increased its holdings in shares of Tilray Brands by 4.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock worth $1,304,000 after buying an additional 6,182 shares during the last quarter. Baader Bank Aktiengesellschaft increased its holdings in shares of Tilray Brands by 17.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 47,938 shares of the company’s stock worth $293,000 after buying an additional 7,226 shares during the last quarter. Finally, IFP Advisors Inc raised its position in shares of Tilray Brands by 14.3% in the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after buying an additional 7,541 shares during the period. 9.35% of the stock is owned by institutional investors and hedge funds.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Unusual options activity provided a bullish trading signal: investors purchased 23,521 TLRY call options, approximately 82% above the stock’s typical daily call volume. This suggests increased speculative interest in further gains.
• Positive Sentiment: Jefferies reiterated its Buy rating, saying Tilray is making progress in its transition toward a diversified consumer-products company. The firm’s view supports the potential for longer-term value from Tilray’s cannabis, beverage and other businesses. Tilray Brands seen creating long-term value through diversified platform, Jefferies says
• Neutral Sentiment: Southern Glazer’s Wine & Spirits completed its acquisition of substantially all of Eagle Rock Distributing’s Colorado assets. The transaction could be relevant to Tilray’s beverage-distribution strategy if it affects industry relationships, but the announcement did not directly identify Tilray or quantify an impact on its results. Southern Glazer’s Wine & Spirits Closes Acquisition of Eagle Rock Distributing Co.
• Negative Sentiment: Jefferies lowered its price target to $19 and reduced fiscal 2027 and 2028 EBITDA estimates after Tilray’s guidance for fiscal 2027 adjusted EBITDA of $68 million to $75 million came in below the roughly $84 million consensus estimate. The lower forecasts highlight continuing profitability concerns.
• Negative Sentiment: Tilray remains in a prolonged downtrend, having lost substantial value this year alongside other cannabis stocks. Its weak recent momentum and history of quarterly losses remain risks despite the current rebound. Tilray Brands stock continues its downward spiral

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.